ABT-414: Preliminary Phase I data

Preliminary data from about 9 evaluable patients with recurrent or unresectable GBM in an open-label, international Phase I trial showed that 0.5, 1 or 1.5 mg/kg IV ABT-414 every other week plus temoz...